Key result
Pre-pregnancy Lp(a) >75 nmol/L shows no association with hypertensive disorders of pregnancy or preterm birth.
Why the study?
Lp(a) is an atherosclerotic risk factor that may influence pregnancy complications, but mechanisms are poorly understood and existing evidence relies on small cross-sectional studies, non-uniform measurement, and isoform-sensitive assays.
Does elevated pre-pregnancy Lipoprotein(a) increase the risk of adverse pregnancy outcomes in Hispanic/Latino women?
Cohort (n=508)
Yes
Does elevated pre-pregnancy Lipoprotein(a) increase the risk of adverse pregnancy outcomes in Hispanic/Latino women?
Pre-pregnancy Lp(a) levels did not show a statistically significant association with adverse pregnancy outcomes in a diverse Hispanic/Latino cohort, though non-linear trends suggest further study is needed.
Answers are grounded in this paper and cite their sources.
Pre-pregnancy Lp(a) >75 nmol/L showed no significant association with pregnancy complications; leaves open non-linear trends and requires larger prospective studies.
Background Lipoprotein(a) [Lp(a)] is an atherosclerotic risk factor that may influence adverse pregnancy complications, although mechanisms remain poorly understood. Evidence linking Lp(a) with pregnancy outcomes relies on small cross-sectional studies, non-uniform Lp(a) measurement across pregnancy, and isoform-sensitive assays. Methods We identified 508 women with singleton live birth >43 weeks after baseline (2008–2011). Self-reported outcomes at second visit include: gestational diabetes mellitus (GDM, n=80 [16%]), hypertensive disorders of pregnancy (HDP, n=55 [11%]), preterm birth (PTB, n=55 [11%]), small for gestational age (SGA, n=37 [8%]), and Birth Weight Z-score (BWZ, n=483). Adverse pregnancy outcome (APO, n=179 [37%]) was defined as presence of GDM, HDP, PTB, or SGA. Confounder-adjusted (age, kidney function, Hispanic/Latino background) logistic regression examined linear, curvilinear, quartile-categorized, and binary risk-threshold (≥75 nmol/L) patterns. Results Baseline mean age was 26.4 (SD=5.8), almost half were of Mexican background, and the Lp(a) median=16.9 nmol/L (range: 2.8–415.1; IQR: 6.7–52.8 nmol/L; n=93 [18%] with Lp(a)>75 nmol/L). Lp(a) >75 nmol/L had an odds ratio of 0.77 for HDP (95%CI: 0.31–1.92) and 0.86 for PTB (95%CI: 0.32–2.32), both imprecise and did not reach statistical significance. The curvilinear model, though imprecise, suggested an inverted U-shaped dose–response pattern for odds of GDM and HDP, while PTB and BWZ showed downward and upward trends, respectively, across increasing Lp(a). Other associations showed no clear pattern. Conclusions Pre-pregnancy Lp(a) may exhibit a U-shaped dose-response with HDP and GDM, and a downward trend in PTB; however, there were no definite associations. Future work with larger samples is needed to understand the physiological implications of Lp(a) for pregnancy.
No takes yet. Share an insight, caveat, or question.
Habib et al. (2026) conducted a cohort in Adverse pregnancy outcomes (n=508). Pre-pregnancy Lipoprotein(a) >75 nmol/L vs. Pre-pregnancy Lipoprotein(a) ≤75 nmol/L was evaluated on Hypertensive disorders of pregnancy (HDP) (OR 0.77, 95% CI 0.31-1.92, p=not statistically significant). Pre-pregnancy Lipoprotein(a) levels >75 nmol/L were not significantly associated with hypertensive disorders of pregnancy (OR 0.77) or preterm birth (OR 0.86) in Hispanic/Latina women.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: